Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burtness

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404)Alan L Ho, Nathan R Foster, Alex J Zoroufy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck CancerJulie E Bauman, Nabil F Saba, Denise Roe, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2019
Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and NeckJong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research GroupShanthi Marur, Shuli Li, Anthony J Cmelak, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Journal of the National Cancer Institute|June 26, 2023
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadershipRebecca A Snyder, Barbara Burtness, May Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404)Alan L Ho, Nathan R Foster, Alex J Zoroufy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck CancerJulie E Bauman, Nabil F Saba, Denise Roe, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2019
Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and NeckJong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research GroupShanthi Marur, Shuli Li, Anthony J Cmelak, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Journal of the National Cancer Institute|June 26, 2023
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadershipRebecca A Snyder, Barbara Burtness, May Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Pageof 19